Form 4 for MDGL MADRIGAL PHARMACEUTICALS, INC.
Accepted 2024-05-23 00:00:00 ET · period of report 2024-05-21 · accession 0000950170-24-064271 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-05-23 | 2024-05-21 | MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev | S - Sale | $231.34 | -1,036 | 5,500 | -16% | -$239.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-21 | S | D | 1,036 | $231.34 | 5,500 | D | — | — |